NEW YORK, Dec. 4 (Xinhua) -- In the first head-to-head test, Eli Lilly's Zepbound obesity drug helped people lose significantly more weight than its main competitor, Novo Nordisk's Wegovy.
People taking Zepbound lost 20.2 percent of their body weight on average after 72 weeks of treatment in the Lilly-sponsored study, compared with a 13.7 percent loss for Wegovy patients, Lilly said on Wednesday.
